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Abstract
In this paper, a literature review is made for the current models of glucose-insulin dynamics of type 2 diabetes patients.
Afterwards, a model is proposed by combining and modifying some of the available models in literature. Finally, a simulation
study is provided to discuss the modified model. The model is proposed as a candidate to be validated with real patients data
in the future.
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1 Introduction
One of the greatest health challenges which faces
humanity in the 21st century is the emergence of type
2 diabetes (T2D) as a global pandemic. More than 415
million were reported to suffer from T2D in 2015 and
the number is expected to reach 642 million by 2040
[5]. Moreover, the global expenses related to T2D are
estimated to be 850 million USD in 2017 and they
are expected to increase [21]. T2D is characterized
by high levels of glucose concentration in the blood.
This increase in glucose levels can cause cardiovascular
diseases and, if left untreated, will lead to organ
failures. For T2D patients, low sensitivity to insulin,
which is the hormone responsible for lowering glucose
concentration in the blood, causes the beta cells in the
pancreas to produce more of it to compensate. This will
eventually weaken the cells and damage them which
in turns will make the body fail to regulate glucose
concentration [2]. Insulin based treatment is initiated at
later stages of the T2D disease when changes in diets and
physical activities accompanied with oral medications
have failed. Clinically, it is difficult to calculate suitable
insulin doses for each specific patient. Therefore, many
patients experience uncontrolled hyperglycemia for a
long period of time until they reach a safe level of glucose
[28]. This happens due to the high variability of each
patient and the different effect of their diet and lifestyle
on insulin sensitivity. Furthermore, many patients suffer
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from hypoglycemic episodes if they overdose on insulin
due to inaccurate calculations. Developing a model for
the glucose-insulin dynamics helps with developing and
testing algorithmic insulin dose guiders that handle
patients variability better and ensure a safe reach
for a desired blood glucose concentration. Moreover,
having a model helps to develop hypoglycemic episodes
alert systems for the patients. Additionally, models for
glucose-insulin dynamics can help medical professionals
with their patients’ treatment plans. In this paper,
a survey of current models and simulators for the
insulin-glucose dynamics in T2D patients is carried out.
After that, a new model is proposed by combining and
modifying some of the models from current literature.
Finally, simulation results are provided to discuss the
introduced model.
2 Litrature Review
In general, there are two main categories of methods
to model systems: first order principles methods, or
data driven methods derived by fitting data to general
mathematical structures such as ARMAX models.
The glucose-insulin dynamical models for T2D patients
based on first order principles can vary with different
degrees of complexity. Generally in the literature, there
exist two main categories of such models: minimal
models and maximal models [6]. Maximal models are
very detailed models which model metabolic functions
at a molecular level. On the other hand, minimal models
are less detailed and rely mostly on compartments
and mass balance equations. While maximal models
provide a great level of accuracy, the amount of different
data which is required to estimate parameters for the
models is large and difficult to obtain from patients
undergoing typical treatment plans. Moreover, the high
accuracy of maximal models provides little relevance
to the accuracy of the general glucose-insulin dynamics
within the human body [6].
In contrast, minimal models consist of compartments
to represent the distribution, diffusion, and production
of glucose and insulin in the body with terms to
represent the interaction between them. Furthermore,
these models include pharmacokinetic equations to
describe exogenous insulin injections and the intake of
other medications. Several simulation oriented models
for type 1 diabetic (T1D) patients were developed
such as the ones in [19][16][14]. The models for T1D
patients can be extended to model T2D patients by
including dynamics for endogenous insulin production
and by obtaining new probability distributions for their
parameters with the use of T2D patients data. As for
already existing T2D models, Cobelli’s model in [7] is
a detailed model for glucose-insulin dynamics which
is intended for simulation use. It includes nonlinear
terms with hybrid differential equations. The model
parameters are mainly estimated from people who do
not suffer from diabetes. However, general parameters
for T2D patients were also estimated using data from
T2D patients. Although the model does not consider
molecular level dynamics, its level of complexity still
requires a variety of measured variables to estimate
parameters for a given patient. In addition to glucose
measurement in the plasma, the model used traced
consumed glucose data, plasma insulin concentration
measurements, and data regarding C-peptides (Amino
Acids molecules which are side product of insulin
secretion). The authors in [7] provided only mean
parameters for T2D patients. They later developed an
official simulator based on an extended version of their
model to account for oral medications, Glucagon, and
physical activities. The simulator is reported to have
joint probability distribution for the parameters of T2D
patients [27]. Nevertheless, these distributions were not
published. Moreover, there are no published material
for the equations and the structure of the extended
model. Another detailed model is recently developed by
[9]. It is an extension from the models in [7][23]. The
model includes the affect of oral medications, Glucagon,
and Glucagon-like peptide-1. The model is provided
with mean parameters. Some of the parameters are
identified from clinical data, while others are taken from
different sources of literature. None of the mentioned
T2D models so far considers injected insulin. A simpler
T2D simulation oriented model with insulin injection is
provided in [22]. It was developed as an extension to
the model in [15] to take into account when both fast
acting and long acting insulin are used for treatment.
The model also uses modulator functions to account for
the circadian rhythm in the glucose-insulin dynamics.
As for parameter estimation, the model requires data of
consumed glucose, glucose concentration in the plasma,
injected insulin, and endogenous insulin concentration
to be identifiable. In [22], parameter estimation was
carried out using data from two different trials with
different types of insulin with a total of 29 T2D
patients. The parameter estimation took into account
inter-individual variety by estimating a mean and a
variance for the parameters. Therefore, the model can
be used to simulate a population of T2D patients. The
model, however, is simple and does not include oral
medications like the one in [25] or glucose ingestion
model as the one in [7]. Another model is the one from
[1]. This model requires plasma glucose measurement
with injected insulin concentration data. Therefore, this
model can be validated, improved, and fitted with data
collected from patients during typical treatment plans.
The model takes the T1D model in [16] and extended it
with a term to describe endogenous insulin production.
The model, however, is simple and can not fully capture
the dynamics of the glucose-insulin system. Probability
distribution for the model parameters can be found in
[1].
For data driven models, severalmethods were attempted
for T1D in [13][10][26] and T2D in [20]. These models
were generally developed to predict and detect hypo-
glycemic risks. However, data driven models are difficult
for the purpose of developing a general model for T2D
patients simulations. One major problem is that when
data is collected from patients, the patients are already
following some form of a feedback control mechanism
between measured glucose levels and injected insulin.
Therefore, fitting models on data from insulin inputs
to glucose output will also include the dynamics of the
feedback mechanism. This is undesired when the model
is intended to test different control algorithms or if it is
intended for the development of control strategies. This
problem can be solved by perturbing the input insulin
doses with time varying functions. However, it is diffi-
cult to impose perturbation on the insulin input for the
patients without affecting their comfort and health.
In this work, a model is proposed based on the ones
in [9] and [7] with modifications to take into account
variable sized meals along the day, physical activity
effect, variable doses of metformin, and the effect of
stress on the glucose-insulin dynamics for T2D patients.
The model is intended to be used as a starting point for
developing an open source simulator for T2D patients
when data is available.
3 Model Description
The model is mainly based on the one from [9] with the
following four main subsystems:
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• Glucose subsystem.
• Insulin subsystem.
• Glucagon subsystem.
• Incretins hormone subsystem.
The glucose and insulin subsystems are modelled as a set
of compartments representing different main parts of the
human body: brain, heart and lungs, guts, liver, kidney,
and peripherals. The flow between these compartments
follows the human blood cycle. As for the glucagon and
the incretins, a single compartment is used for each one
of them as it is assumed that glucagon and incretins
have equal concentration in all the body parts. The
compartments include metabolic production and uptake
rates generally defined as following:
r =M IMGMΓrb (1)
WhereM I ,MG, andMΓ aremultiplicative quantities for
the effect of insulin, glucose, and glucagon respectively,
and rb is the basal metabolic rate. The general form for
the multiplicative quantities representing the effect of a
substance with concentration X is given as:
MX =
a+ b tanh
[
c
(
X/Xb − d
)]
a+ b tanh[c(1− d)]
(2)
Where Xb is the concentration at basal condition, and
a, b, c, and d are model parameters. The pancreas has
a different nonlinear and hybrid model. In addition, a
glucose ingestion model based on [7] is included as in
[25] but modified to handle multiple meals along the day.
Moreover, metformin and vildagliptin oral treatment
models are included based on [24] and [17] respectively
as in [9] but with a modification on the oral metformin
model to handle different oral doses along the treatment.
Additionally, a physical activity model based on [4]
is added to the model. Furethermore, long acting and
fast acting insulin injection models based on [18] are
added. Finally, stress is included as a factor αs ∈ [0, 1]
as in [11]. The main model includes parameters that
were estimated by [23] for a healthy 70 kg man. The
work in [25] considered a subset of these parameters
to be estimated for the diabetic cases. Parameters
for the different added models are taken from their
corresponding literature. Figure 1 shows an overview of
the model. In the following subsections, the added and
modified models and states will be discussed. The full
model equations are provided in appendix A.
3.1 Glucose Absorption Model
The model used for glucose absorption in [9] considers
only one glucose meal and was used for oral glucose tests
where they give the patient an oral glucose amount and
ask them to fast while they collect data. The model is
given as:
dqSs
dt
= −k12qqSs (3a)
dqSl
dt
= −kemptqSl + k12qqSs (3b)
dqint
dt
= −kabsqint + kemptqSl (3c)
kempt = kmin +
kmax − kmin
2
{
tanh
[
ϕ1
(
qSs + qSl − kϕ1DNq
)]
− tanh
[
ϕ2
(
qSs + qSl − kϕ2DNq
)]
+ 2
} (3d)
ϕ1 =
5
2DNq(1− kϕ1)
(3e)
ϕ2 =
5
2DNq(kϕ2)
(3f)
Ra = fqkabsqint (3g)
Where qSs(0) = DNq [mg] is the oral glucose quantity,
Ra is the rate of glucose appearance in the blood, fq
is an absorption factor, k12 [min
−1] and kabs [min
−1]
are the rate constants for glucose transfer to stomach
and glucose absorption in the intestines respectively,
kempt [min
−1] is a rate parameter for emptying the
stomach of glucose to the intestines. This parameter
can have values between kmin and kmax depending on
the glucose dose size DNq. In order to make the model
handle different meals with different time instants, the
parameter DNq needs to be modified according to the
meal sizes and time. The following are the proposed
modifications:
dqSs
dt
= −k12qqSs +
Nq(t)∑
i=1
Diδ(t− ti), i ∈ Z+ (4a)
dDt
dt
= −ktDt +
Nq(t)∑
i=1
Diδ(t− ti) (4b)
dDNq
dt
= kt
(
Di −DNq
)
+
Nq(t)∑
i=1
Dtδ(t− ti) (4c)
Where δ(t − ti) is the Dirac delta distribution, ti is the
time instance for meal i, Nq(t) is the integer number
of meals until time t, Di [mg] is the amount of oral
glucose intake. The state Dt is introduced to handle the
accumulation of glucose oral meals with a decay factor
kt [min
−1] in order to remove the effect of meals with
time. With that, parameterDNq is now a state updated
by Dt each time a new meal is consumed and made to
converge to the last givenmeal amountDi with the same
rate factor kt such that it converges to the original model
with time if no meal is consumed afterwards. Parameters
fq, kϕ1 , and kϕ2 are known and taken from [7]. The rest
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Fig. 1. A summary of the overall model.
of the parameters, k12q, kmin, kmax, kabs, and kt are to
taken to be the mean parameters which were estimated
in [25]. The introduced parameter kt has no estimate.
Therefore, it is assumed to be equal to kabs.
3.2 Insulin Injection Model
The insulin injection model is based on the one proposed
in [18]. Both fast and long acting insulin analogues
treatments are considered for the model. When analogue
insulin is injected, it dissociates from its hexameric form
to dimers and monomers which then can penetrate the
capillary membrane and get absorbed into the plasma.
For fast acting insulin, only two compartments are
considered: a compartment for insulin in its hexameric
form, and a compartment for insulin in its dimeric and
monomeric form. The following are the equations for fast
acting insulin:
dHfa
dt
=
Nfa(t)∑
i=1
δ (t− ti)
1
VI
ufi
− pfa
(
Hfa(t)− qfaD
3
fa(t)
) (5a)
dDfa
dt
= pfa
(
Hfa(t)− qfaD
3
fa(t)
)
−
bfaDfa(t)
1 + IPF (t)
(5b)
Where Hfa [mU/dl] is the concentration of injected
fast acting insulin in its hecameric form, Dfa [mU/dl]
is the concentration of insulin in its diameric and
monomeric form, Nfa(t) is the number of injected fast
acting insulin doses until time t, ufi [mU] is the amount
of injected fast acting insulin, VI [dl] is the injection
volume, bfa [min
−1] is a constant for the infusion of fast
acting insulin into the body, pfa [min
−1] is a constant
diffusion parameter, qfa [dl
2/mU2] is a constant such
that pfaqfa is the parameter for fast acting insulin
dimers converting back to hexamers, and IPF [mU/dl]
is the insulin concentration in the interstitial periphery
compartment. Parameters for Lispo and Aspart insulin
injection are reported in [18]. As for long acting insulin,
an extra state is added to take into account the increased
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delay in the dissociation of hexameric insulin to dimers
and monomers:
dBla
dt
=
Nla(t)∑
i=1
δ (t− ti)
1
VI
uli − klaBla
Cmax
1 +Hla
(6a)
dHla
dt
= klaBla
Cmax
1 +Hla
− pla
(
Hla − qlaD
3
la
)
(6b)
dDla
dt
= pla
(
Hla − qlaD
3
la
)
−
blaDla
1 + IPF
(6c)
Where Bla [mU/dl] is the added bound state for the
concentration of hexameric insulin before diffusing,
Hla [mU/dl] is the concentration of injected long acting
insulin in its hecameric form, Dla [mU/dl] is the
concentration of injected insulin in its diameric and
monomeric form, Nla(t) is the number of injected long
acting insulin doses until time t, uli [mU] is the amount
of long acting insulin dose at time ti, bla [min
−1] is a
constant for the infusion of long acting insulin into the
body, pla [min
−1] is a constant diffusion parameter for
long acting insulin, qla [dl
2/mU2] is a constant such
that plaqla is the parameter for long acting insulin
dimers converting back to hexamers, kla [min
−1] is a
constant absorption rate, and Cmax is a dimensionless
maximum transmission capacity constant. Parameters
for insulin Glargin are reported in [18]. The injected
insulin enters the interstitial periphery compartment
with the following rate:
rInj = V
I
PF
rlablaDla
1 + IPF
+ V IPF
rfabfaDfa
1 + IPF
(7)
Where rla, rfa ≤ 1 are the fractions of long acting
and fast acting insulin that get to the periphery
compartment, and V IPH [dl] is the volume of the
interstitial compartment.
3.3 Metformin
The metformin model, including the pharmacokinetic
and its interaction with full glucose-insulin dynamical
models, is based on [24]. The pharmacokinetic model of
metformin in [24] is given as following:
dMGL
dt
= −MGL
(
kgo + kgg
)
+MO (8a)
dMGW
dt
=MGLkgg +MPkpg −MGWkgl (8b)
dML
dt
=MGWkgl +MPkpl −XLklp (8c)
dMP
dt
=MLklp −MP
(
kpl + kpg + kpo
)
+MGL
(8d)
Where MGL [µg] is the metformin amount in the
gastrointestina lumen, parameters kgo, kgg, kpg, kgl, kpl,
klp, kpo [min
−1] are transfer rate constants between the
compartments, andMO is the flow rate of orally ingested
metformin which is modelled as:
MO = Ae
−αM t +Be−βM t (9)
Where A,B [µg/min] and αM , βM [min
−1] are constant
parameters that were identified in [24]. These param-
eters were identified with data in which patients were
taking only 0.5 [µg] doses of metformin. Therefore, the
model is modified in this work to take into account dif-
ferent amount of doses at different times by introducing
the following:
dMO1
dt
= αMMO1 +
NM (t)∑
i=1
δ (t− ti)uMi (10a)
dMO2
dt
= βMMO2 +
NM (t)∑
i=1
δ (t− ti)uMi (10b)
MO = ραM01 + ρβM02 (10c)
With NM (t) is the number of consumed doses of
metformin until time t, uMi [µg] is the amount of
metformin consumed at time ti, and the constants ρα =
A/(0.5 [µg]) [min−1] and ρβ = B/(0.5 [µg]) [min
−1]
are rate parameters. The parameters for the model are
estimated and provided in [24].
3.4 Physical Activity Model
Physical activity in the model is introduced by consid-
ering the model developed in [4]. The model was devel-
oped for a T1D model based on [3]. The model considers
the change of the heart beat following a physical activ-
ity to be the stimulus of two states E1 and E2 which are
dimensionless:
dE1
dt
= −
1
tHR
+
1
tHR
(HR−HRb) (11a)
dE2
dt
= −
(
ge(E1) +
1
τe
)
E2 + ge(E1) (11b)
g(E1) =
(
E1
aeHRb
)ne
1 +
(
E1
aeHRb
)ne (11c)
Where tHR, τe2 [min
−1] are time constants,HR, HRb [bpm]
are the current and rest heart rates respectively, and the
parameters ae, ne are dimensionless parameters. The
first state E1 is used directly as a stimulus to increase
the insulin-independent glucose uptake in response to
a physical activity while the state E2 is used for the
longer lasting change of insulin action on glucose. The
glucose and insulin model structure in [4] is simpler
than the one considered in this work. Nevertheless,
the inclusion of the physical activity for the model in
5
this work is paralleled to how other models included it
such as the one in [8]. With that, the effect of the state
E1 is included as an increase in the clearance rate of
glucose in the periphery interstitial fluid compartment
with a constant parameter βe [1/bpm]:
1
TG
P
(1 + βe)E1
where 1
TG
P
[min−1] is the clearance rate for glucose in
the periphery interstitial fluid compartment. As for the
effect on insulin action, the state E2 is introduced for
the metabolic rates rPGU in the interstitial fluid pe-
riphery compartment of glucose and rHGU in the liver
compartment with a constant αe as following:
• An increase in rPGU : (1 + αeE2) rPGU
• An increase in rHGU : (1 + αeE2) rHGU
The parameters for the physical activity are estimated
in [4]. Paralleling [8], the values of these parameters is
assumed to be the same as [4] except of αe which was
tuned to have the same effect as in [4].
3.5 Stress Effect
The stress effect was included in [11] as an input that
takes values between 0 and 1 representing the severity
of stress. In [11], the effect of stress was included as a
multiplicative factor 1+αs to the glucose and glucagon
production rates. This is based on the fact that stress
causes a direct increase in the pancreatic glucagon
production through an increase in catecholamines which
in turns drives an increase of glucose production in the
liver [29]. In addition, stress was also included as a
multiplicative factor 1 − αs to the pancreatic insulin
secretion rate based on [29]. Similarly in this work, the
effect of stress is included in the model as following:
• An increase in the plasma glucagon release rate
rPΓR: (1 + αs) rPΓR.
• An increase in the hepatic glucose production rate
rHGP : (1 + αs) rHGP .
• A decrease in the pancreatic insulin release rate
rPIR: (1− αs) rPIR
4 Simulation Results
In this section, simulation results for different cases
are included to discuss the modified model. The model
was implemented in Matlab and the software can be
obtained upon request from one of the authors. The
parameters are taken to be mean parameters from the
corresponding literature for the different models except
for αe that was tuned to make the response similar to
the one in [4]. The values of the parameters can be
found in appendix B. All the simulation cases start with
initial condition of GPC(0) = 10 [mmol/L] for glucose
concentration in the central periphery compartment and
IPF = 1 [mU/dl] for the insulin concentration in the
interstitial fluid periphery compartment. The patient
is assumed to be having three meals each day with a
corresponding glucose net amount of 5 [g] for the first
meal, 5 [g] for the second meal, and 50 [g] for the third
meal.
4.1 Insulin Injection
For this case, the patient is assumed to be taken a
Glargin long acting insulin dose of 30 [U] each morning
and a Lispo fast acting insulin dose of 0.5 [U] at the same
time for the third meal. The results are shown in Figure
2. The long acting insulin raise the level of insulin during
the day in general and reduces glucose concentration
in the same manner. The fast acting insulin raises the
insulin levels for the third meal so it does not cause a
large spike in glucose. The figure also shows the natural
body insulin response to increases of glucose upon the
consumption of meals where fast acting insulin is not
injected. The natural body insulin response is seen
clearly when the insulin rise in a more apparent manner
in the plasma rather than the peripherals.
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Fig. 2. Simulation results with insulin injections.
4.2 Metformin and Stress
As for this case, the patient is assumed to be taking a
metformin oral dose of 0.6 [µg] each morning without
any insulin doses. However, the patient experiences
stress with severity αs = 0.3 during the second day
of the simulation. The simulation results are shown in
Figure 3. The Metformin effect can be seen especially
in the last day. It decreases glucose concentration by
enhancing the sensitivity to insulin. At the same time,
the body naturally reduces its production of insulin.
Additionally, it can be seen how stress can raise the
glucose concentration and decrease insulin sensitivity.
4.3 Metformin and Physical Activity
For this simulation, the patient is exercising for an hour
each day after three hours of the last meal in addition
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Fig. 3. Simulation results with Metformin oral doses and
stress effect.
to the metformin medication. The exercise raises the
heart rate by 30 [bpm] from a rest value of 40 [bpm]
during the entire hour. Figure 4 shows the results. The
effect of physical activity can be seen by an apparent
decrease in the peripherals glucose concentration during
the exercise followed by a prolonged effect that is caused
by the enhancement of insulin action on glucose using
the state E2. The same effect is discussed in [4].
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Fig. 4. Simulation results with Metformin oral doses and
physical activity.
5 Conclusion and Future Work
The proposed model is shown to be able to be used
with multiple glucose meal sizes, different metformin
doses, physical activity, insuling injections, and stress.
The model, however, still neeed to be confirmed with
real patients data. Moreover, real patients data can be
used to estimate joint probability distribution to model
a population of T2D patients.
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A Full Model Equations
A.1 Glucose Sub-Model
Applying mass balance equations over the compart-
ments for glucose, the following equations are obtained:
V GBC
dGBC
dt
= QGB (GH −GBC)−
V GBF
TGB
(GBC −GBF )
(A.1a)
V GBF
dGBF
dt
=
V GBF
TGB
(GBC −GBF )− rBGU (A.1b)
V GH
dGH
dt
= QGBGBC +Q
G
LGL +Q
G
KGK
+QGPGPC +Q
G
HGH − rRBCU
(A.1c)
V GG
dGG
dt
= QGG (GH −GG)− r
m
GGU +Ra (A.1d)
V GL
dGL
dt
= QGAGH +Q
G
GGG −Q
G
LGL
+
(
(1 + stress)rmHGP − (1 + αeE2) rHGU
)
(A.1e)
V GK
dGK
dt
= QGK (GH −GK)− rKGE (A.1f)
V GPC
dGPC
dt
= QGP (GH −GPC)−
V GPF
TGP
(GPC −GPF )
(A.1g)
V GPF
dGPF
dt
=
V GPF
TGP
(GPC
− (1 + βeE1)GPF
)
− (1 + αeE2) r
m
PGU
(A.1h)
Where Gi [mg/dl] is glucose concentration for each
compartment i, QGi [dl/min] is the vascular blood
flow for the glucose compartment i, V Gi [dl] is the
volume of compartment i, rxP , rxU aremetabolic glucose
production and uptake rates respectively. The following
are the meanings of each subscript in the model:
• B: Brain
• BC: Brain capillary space
• BF: Brain interstitial fluid
• H: Hear
• G: Guts
• L: Liver
• K: Kidney
• P: Periphery
• PC: Periphery capillary space
• PF: Periphery interstitial fluid
• BGU: Brain glucose uptake
• RBCU: Red blood cell glucose uptake
• GGU: Gut glucose uptake
• HGP: Hepatic glucose production
• HGU: Hepatic glucose uptake
• KGE: Kidney glucose excretion
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• PGU: Peripheral glucose uptake
The metabolic rates for the glucose subsystem are given
as:
rPGU =M
I
PGUM
G
PGUr
b
PGU , r
b
PGU = 35 (A.2a)
rHGP =M
I
HGPM
G
HGPM
Γ
HGP r
b
HGP , r
b
HGP = 35
(A.2b)
rHGU =M
I
HGUM
G
HGUr
b
HGU , r
b
HGU = 20 (A.2c)
rKGE =
{
71 + 71 tanh
[
0.11 (GK − 460)
]
GK < 460
−330 + 0.872GK GK ≥ 460
(A.2d)
rBGU = 70, rRBCU = 10, rGGU = 20 (A.2e)
Where:
M IPGU =
7.03 + 6.52 tanh
[
c
(
IPF /I
B
PF − d
)]
7.03 + 6.52 tanh[c(1 − d)]
(A.3a)
MGPGU = GPF /G
b
PF (A.3b)
d
dt
M IHGP = 0.04
(
M I∞HGP −M
I
HGP
)
(A.3c)
M I∞HGP =
1.21− 1.14 tanh
[
c
(
IL/I
B
L − d
)]
1.21− 1.14 tanh[c(1− d)]
(A.3d)
MGHGP =
1.42− 1.41 tanh
[
c
(
GL/G
B
L − d
)]
1.42− 1.41 tanh[c(1− d)]
(A.3e)
MΓHGP = 2.7 tanh
[
0.39Γ/ΓB
]
− f (A.3f)
d
dt
f = 0.0154


(
2.7 tanh
[
0.39Γ/ΓB
]
− 1
2
)
− f


(A.3g)
d
dt
M IHGU = 0.04
(
M I∞HGU −M
I
HGU
)
(A.3h)
M I∞HGU =
2.0 tanh
[
c
(
IL/I
B
L − d
)]
2.0 tanh[c(1− d)]
(A.3i)
MGHGU =
5.66 + 5.66 tanh
[
c
(
GL/G
B
L − d
)]
5.66 + 5.66 tanh[c(1− d)]
(A.3j)
Note that some of these rates have a constant numeri-
cal value. In addition, parameters a and b for the multi-
plicative quantities are substituted with numerical val-
ues. These numerical values are the ones estimated for a
healthy man of 70 Kg weight. Parameters c and d were
left for the estimation in case of a diabetic patient as in
[25]. The following rates are modified with the effect of
metformin as following:
rmGGU = (1 + EGW ) rGGU (A.4a)
rmHGP = (1− EL) rHGP (A.4b)
rmPGU = (1 + EP ) rPGU (A.4c)
Where EGW , EL, and EP are positives coefficients
which depend on the amount of metformin in the
gastrointestina wall (GI) MGW [µg], liver ML [µg],
and peripherals Mp [µg] respectively. These coefficients
increase (or decrease) the glucose uptake (or production)
as seen in (A.4). The equations for these coefficients are
given as following:
EGW =
νGW,max × (MGW )
nGW(
ϕGW,50
)nGW
+ (MGW )
nGW
(A.5a)
EL =
νL,max × (ML)
nL(
ϕL,50
)nL
+ (ML)
nL
(A.5b)
EP =
νP,max × (MP )
nP(
ϕP,50
)nP
+ (XP )
nP
(A.5c)
Where νGW,max, νL,max, νP,max are parameters to
represent the maximum effect of metformin in each
one of its corresponding compartments, ϕGW,50, ϕGI,50,
ϕGI,50 [µg] are the masses of metformin within the
different compartments to produce half of its maximum
effect, and nGW , nL, and nP are shape factors.
A.2 Incretins Sub-Model
The incretins hormones aremetabolic hormones released
after eating a meal to stimulate a decrease in blood glu-
cose levels. For T2D patients, Glucagon-Like-Peptide-1
(GLP-1) is the most active incretin [12]. GLP-1 is then
modelled with the following two compartments as in [9]:
dψ
dt
= ζkemptqSl −
1
τψ
ψ (A.6a)
V Ψ
dΨ
dt
=
1
τψ
ψ −
[
Kout + (RmaxC −DRc)Cf2
]
Ψ
(A.6b)
Where τψ [min
−1] is a time constant for the release and
absorption of GLP-1 to the blood stream upon consum-
ing a meal, V Ψ [dl] is the volume of the GLP-1 compart-
ment,DRc [nmol] is the amount of Dipeptidyl peptidase-
4 (DPP-4) in the central compartment deactivated by
the drug vildagliptin, Kout [min
−1] is a clearance con-
stant for GLP-1 independently of the amount of DPP-4,
and (RmaxC−DRc) is the amount of available activated
DPP-4 in the blood plasma with RmaxC [nmol] being
the maximum amount of active DPP-4 in the absence of
the vildagliptin. Cf2 [min
−1nmol−1] is a proportionality
factor for the elimination of GLP-1 by active DPP-4 [17].
Parameters τψ and ζ are estimated in [25] when other
incretins than GLP-1 are considered and later modified
in [25] to account for vildagliptin treatment. Parameters
Kout, RmaxC , and Cf2 were estimated in [17] together
with the parameters for the vildagliptin model described
in subsection A.6.
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A.3 Glucagon Sub-Model
The glucagon subsystem consists of one compartment
as it is assumed to have the same concentration over all
the body:
V Γ
dΓ
dt
= (1 + αs)rPΓR − 9.1Γ (A.7a)
rPΓR =M
G
PΓRM
I
PΓRr
b
PΓR, r
b
PΓR = 9.1 (A.7b)
MGPΓR = 1.31− 0.61 tanh

1.06
(
GH
GBH
− 0.47
)
(A.7c)
M IPΓR = 2.93− 2.09 tanh

4.18
(
IH
IBH
− 0.62
)

(A.7d)
Where rPΓR is the plasma glucagon release rate. The
state Γ represent a normalized glucagon state with
respect to its basal value. This is done since it is difficult
in practice to obtain glucagon measurements for each
subject in order to initialize the state. Therefore for this
model, the basal glucagon state is 1.
A.4 Insulin Sub-Model
Applying mass balance equations over the insulin
compartments will yield the following:
V IB
dIB
dt
= QIB (IH − IB) (A.8a)
V IH
dIH
dt
= QIBIB +Q
I
LIL +Q
I
KIK
+QIP IPV −Q
I
HIH
(A.8b)
V IG
dIG
dt
= QIG (IH − IG) (A.8c)
V IL
dLL
dt
= QIAIH +Q
I
GIG −Q
I
LIL
+ (1− αs)rPIR − rLIC
(A.8d)
V IK
dIK
dt
= QIK (IH − IK)− rKIC (A.8e)
V IPC
dIPC
dt
= QIP (IH − IPC)−
V IPF
T IP
(IPC − IPF )
(A.8f)
V IPF
dIPF
dt
=
V IPF
T IP
(IPC − IPF )− rPIC + rInj (A.8g)
Where rLIC , rKIC , and rPIC are the liver, kidney, and
peripherals insulin clearance rates respectively and are
defined as following:
rLIC = 0.4
[
QIAIH +Q
I
GIG −Q
I
LIL + rPIR
]
(A.9a)
rKIC = 0.3Q
I
KIK (A.9b)
rPIC =
IPF[(
1−0.15
0.15QI
P
)
−
20
V I
PF
] (A.9c)
the pancreas insulin release is calculated by the
following:
rPIR =
S
Sb
rbPIR (A.10)
Where S [U/min] is the pancreas secreted insuln rate,
and Sb, rbPIR are the basal values. The model for S and
Sb is described in subsection A.5.
A.5 Pancreas Sub-Model
The model consists of two main compartments: a
large insulin storage compartment ms [µg] and a
small labile insulin compartment ml [µg]. The flow
of insulin from the storage compartment to the labile
insulin compartment is dependent on a dimensionless
factor P with a proportionality constant γ [µg/min].
The factor P depends on a dimensionless glucose-
enhanced excitation factor represented by X and GLP-
1 through a linear compartment with constant first
order rate α [min−1]. Upon a glucose stimulus, the
glucose-enhanced excitation factor X will increase
instantaneously depending on the glucose increase in
the plasma GH . In addition, a dimensionless inhibitor
R for X will increase in response to X through a linear
compartment with a first order constant rate β [min−1].
During that increase, the secreted insulin S will depend
directly on both X and its inhibitor R together with
GLP-1. Afterwards when R reaches X or X starts
decreasing after R reaching it, the insulin secretion rate
will only depend onX and GLP-1. The following are the
equations of the model:
dms
dt
= Klml −Ksms − γP (A.11a)
dml
dt
= Ksms −Klml + γP − S (A.11b)
dP
dt
= α(P∞ − P ) (A.11c)
dR
dt
= β(X −R) (A.11d)
S =
{[
N1P∞ +N2 (X −R) + ζ2Ψ
]
ml X > R
(N1P∞ + ζ2Ψ)ml X ≤ R
(A.11e)
P∞ = X
1.11 + ζ1Ψ (A.11f)
X =
G3.27H
1323.27 + 5.93G3.02H
(A.11g)
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Where Kl [min
−1] and Ks [min
−1] are the rates
for the flow between the labile and storage insulin
compartments independently of P , N1 [min
−1] and
N2 [min
−1] are constant parameters that represent the
effect of P and (X −R) on the insulin secretion rate
respectively, and ζ1 [l/pmol], ζ2 [l/pmol] are constant
parameters to represent the effect of GLP-1 on P∞ and
the insulin secretion rate. For initializing the model and
calculating the basal values, the storage compartment
is assumed to be large enough for it to be constant.
Therefore, writing the mass balance for the storage
compartment at zero glucose concentrationwill yield the
following:
Ksms = Klml0 (A.12)
Where ml0 is the labile insulin concentration at zero
glucose concentration. This parameter in [23] is provided
with a value of 6.33U for a healthy 70 kg man.
A.6 Vildagliptin
The vildagliptin model is based on [17]. The absorption
of orally ingested vildagliptin is modelled by two
compartments as following:
dAG1
dt
= −ka1AG1 +
Nv(t)∑
i=1
δ (t− ti) fvuvi (A.13a)
dAG2
dt
= ka1 ×AG1 − ka2 ×AG2 (A.13b)
Where AG1, AG2 [nmol] are the amount of vildagliptin
in the gut and absorption compartments respectively,
Nv(t) is the number of oral vildagliptin doses until time
t, uvi [nmol] is the amount of consumed vildagliptin, fa
is the bioavailability of vlidagliptin, and ka1, ka2 [min
−1]
are rate absorption parameters. After that, the model
contains a central and a peripheral compartment for
the vildagliptin and the vildagliptin-DPP-4 complex
(deactivated DPP-4):
dAc
dt
= ka2AG2 −
CL + CLic
VC
AC +
CLic
Vp
Ap
−
(RmaxC −DRC) kv2
Ac
VC
Kvd +
Ac
Vc
+ koffDRC
(A.14a)
dAp
dt
= CLic
(
Ac
Vc
−
Ap
Vp
)
−
(
RmaxP −DRp
)
kv2
Ap
Vp
Kvd +
Ap
Vp
+ koffDRp
(A.14b)
dDRC
dt
=
(RmaxC −DRC) kv2
AC
VC
Kvd +
AC
VC
−
(
koff + kdeg
)
DRC
(A.14c)
dDRP
dt
=
(RmaxP −DRP ) kv2
AP
VP
Kvd +
AP
VP
−
(
koff + kdeg
)
DRP
(A.14d)
Where AC , AP [nmol] are the amounts of vildagliptin in
the central and peripheral compartments respectively,
CL [l/h] is a non-saturable clearance, CLic [l/h] is
the inter-compartmental clearance, Vc, Vp [l] are the
volumes of the central and peripheral compartments
respectively, k2v [h
−1] is a parameter added for the slow
tight binding of vildagliptin to DPP-4, kdv [nmol/l] is
the equilibrium dissociation constant, koff [h
−1] is a rate
constant for the dissociation of intact vildaglptin from
DPP-4, RmaxP [nmol] is the maximum possible amount
of DPP-4 in the peripheral compartment, kdeg [h
−1] is a
rate constant for the hydrolysis of vildagliptin by DPP-
4, and DRP [nmol] is the amount of deactivated DPP-4
in the peripheral compartments.
B Parameters Mean Values
Table B.1 includes the values of the parameters which
were used in the simulation.
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V GBC 3.5 V
G
BF 4.5 V
G
H 3.5 V
G
L 25.1
V GG 11.2 V
G
K 6.6 V
G
PC 10.4 V
G
PF 67.4
V IB 0.26 V
I
H 0.99 V
I
G 0.94 V
I
L 1.14
V IK 0.51 V
I
PC 0.74 V
I
PF 6.74 V
Γ 6.74
QGB 5.9 Q
G
H 43.7 Q
G
A 2.5 Q
G
L 12.6
QGG 10.1 Q
G
K 10.1 Q
G
P 12.6 Q
I
B 0.45
QIH 3.12 Q
I
A 0.18 Q
I
K 0.72 Q
I
P 1.05
QIG 0.72 Q
I
L 0.9 T
G
B 2.1 T
G
P 5.0
T IP 20.0 fq 0.9 kφ1 0.68 kφ2 0.00236
k12q 0.08 kmin 0.005 kmax 0.05 kabs 0.08
cIPGU 0.067 c
I
HGP∞ 1.59 c
G
HGP 0.62 c
I
HGU∞ 1.72
cGHGU 2.03 d
I
PGU 1.126 d
I
HGP∞ 0.683 d
G
HGP 0.14
dIHGU∞ 0.023 d
G
HGU 1.59 ml0 6.33 ζ1 0.0026
ζ2 0.99e
−4 Kl 0.3621 Ks 0.0572 γ 2.366
α 0.615 β 0.931 N1 0.0499 N2 0.00015
V Ψ 11.31 Kout 68.3041 Cf2 21.1512 tψ 35.1
RmaxC 5.0 ζ 8.248 fv 0.772 ka1 0.021
ka2 0.0175 CL 0.6067 CLic 0.6683 Vp 97.3
koff 0.0102 RmaxP 13 kdeg 0.0018 Vc 22.2
Kvd 71.9 kv2 0.39 kgo 1.88e
−4 kgg 1.85e
−4
kpg 4.13 kgl 0.46 kpl 0.00101 klp 0.91
kpo 0.51 νGW,max 0.486 νL,max 0.378 νP,max 0.148
nGW 2.0 nL 2.0 nP 5.0 φGW,50 431.0
φL,50 521.0 φP,50 1024.0 ρα 54 ρbeta 54
αM 0.06 βM 0.1 pla 0.5 rla 0.2143
qla 3.04e
−10 bla 0.025 Cmax 15.0 kla 2.35e
−5
pfa 0.5 rfa 0.2143 qfa 1.3e
−11 bfa 0.0068
tHR 5.0 ne 4.0 ae 0.1 τe 600
αe 2.974 βe 3.39e
−4
Table B.1
Parameters Values
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